GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rebus Hldgs Inc (OTCPK:RBSH) » Definitions » ROE %

Rebus Hldgs (Rebus Hldgs) ROE % : Negative Equity% (As of Jun. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Rebus Hldgs ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Rebus Hldgs's annualized net income for the quarter that ended in Jun. 2023 was $0.17 Mil. Rebus Hldgs's average Total Stockholders Equity over the quarter that ended in Jun. 2023 was $-5.63 Mil. Therefore, Rebus Hldgs's annualized ROE % for the quarter that ended in Jun. 2023 was Negative Equity%.

The historical rank and industry rank for Rebus Hldgs's ROE % or its related term are showing as below:

RBSH' s ROE % Range Over the Past 10 Years
Min: -1993.23   Med: -1030.8   Max: Negative Equity
Current: Negative Equity

During the past 13 years, Rebus Hldgs's highest ROE % was Negative Equity%. The lowest was -1,993.23%. And the median was -1,030.80%.

RBSH's ROE % is ranked better than
99.93% of 1359 companies
in the Biotechnology industry
Industry Median: -44.08 vs RBSH: Negative Equity

Rebus Hldgs ROE % Historical Data

The historical data trend for Rebus Hldgs's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rebus Hldgs ROE % Chart

Rebus Hldgs Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - Negative Equity -

Rebus Hldgs Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - Negative Equity Negative Equity - Negative Equity

Competitive Comparison of Rebus Hldgs's ROE %

For the Biotechnology subindustry, Rebus Hldgs's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rebus Hldgs's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rebus Hldgs's ROE % distribution charts can be found below:

* The bar in red indicates where Rebus Hldgs's ROE % falls into.



Rebus Hldgs ROE % Calculation

Rebus Hldgs's annualized ROE % for the fiscal year that ended in Dec. 2022 is calculated as

ROE %=Net Income (A: Dec. 2022 )/( (Total Stockholders Equity (A: Dec. 2021 )+Total Stockholders Equity (A: Dec. 2022 ))/ count )
=-1.02/( (-5.022+-5.237)/ 2 )
=-1.02/-5.1295
=N/A %

Rebus Hldgs's annualized ROE % for the quarter that ended in Jun. 2023 is calculated as

ROE %=Net Income (Q: Jun. 2023 )/( (Total Stockholders Equity (Q: Mar. 2023 )+Total Stockholders Equity (Q: Jun. 2023 ))/ count )
=0.172/( (-5.657+-5.61)/ 2 )
=0.172/-5.6335
=Negative Equity %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2023) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Rebus Hldgs  (OTCPK:RBSH) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2023 )
=Net Income/Total Stockholders Equity
=0.172/-5.6335
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(0.172 / 0)*(0 / 0.007)*(0.007 / -5.6335)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*N/A
=ROA %*Equity Multiplier
=N/A %*N/A
=Negative Equity %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2023 )
=Net Income/Total Stockholders Equity
=0.172/-5.6335
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (0.172 / 0.172) * (0.172 / -0.436) * (-0.436 / 0) * (0 / 0.007) * (0.007 / -5.6335)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * -0.3945 * N/A % * 0 * N/A
=Negative Equity %

Note: The net income data used here is four times the quarterly (Jun. 2023) net income data. The Revenue data used here is four times the quarterly (Jun. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Rebus Hldgs ROE % Related Terms

Thank you for viewing the detailed overview of Rebus Hldgs's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rebus Hldgs (Rebus Hldgs) Business Description

Traded in Other Exchanges
N/A
Address
2629 Townsgate Road, Suite 215, Westlake Village, CA, USA, 91361
Rebus Hldgs Inc is an early-stage, pre-revenue, pharmaceutical company that is focused on the development of prodrug cancer therapeutics for the treatment of disease. The company along with its subsidiaries is engaged in the production of small-molecule adenosine receptor modulators. Adenosine is an extracellular signaling molecule that regulates multiple aspects of tissue function and specifically plays a role in immunity and inflammation.
Executives
John Robison Montgomery director 7647 BIRCHWOOD HILL RD, CROZET VA 22932
Richard E Buller director C/O CELCUITY INC., 16305 36TH AVE. N., #100, MINNEAPOLIS MN 55446
Claire Thom director 31200 VIA COLINAS, #200, WESTLAKE VILLAGE CA 91362
Ronald L Shazer officer: Chief Medical Officer C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, STE 700, SAN DIEGO CA 92122
Christopher P. Lowe director, officer: President and CEO 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258
Scott Varde Ogilvie director 10880 WILSHIRE BLVD, SUITE 950, LOS ANGELES CA 90024
Bo Jesper Hansen director BIRKENWEG 16, MEGGEN V8 6045
Peter E Grebow director 41 MOORES ROAD, FRAZER PA 19355
Craig A Dionne director, 10 percent owner, officer: CEO,CFO, President 9901 IH 10 WEST, SUITE 800, SAN ANTONIO TX 78230
Russell Richerson 10 percent owner, officer: COO, Secretary 2511 N LOOP 1604 W, SUITE 204, SAN ANTONIO TX 78258
Kihong Kwon 10 percent owner 1015 E. CHAPMAN AVE, SUITE 201, FULLERTON CA 92831